The growing demand for novel drugs, which hold potential for the treatment of previously untreatable intracellular targets has resulted in an adjacent and urgent need for efficient delivery
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Non-Viral Drug Delivery Systems: Focus on Intracellular Technologies and Intracellular Biologics Market, 2021-2030 report features an extensive study of the current landscape and the likely future opportunities in intracellular drug delivery technologies market for the next 10 years.
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for intracellular drug delivery technologies. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2021-2030.
Workers in the Biond Biologics lab in Misgav, Israel (Courtesy)
The anti-cancer drug developed by Biond Biologics, which the Israeli startup will now try on humans in clinical trials with France-based multinational Sanofi, takes a multipronged approach to fighting tumors, activating three kind of cells in the immune system at the same time.
Paris-based multinational pharma firm Sanofi signed a licensing agreement earlier this month for Biond’s flagship anti-tumor drug BND-22, a cancer immunotherapy medication.
Under the terms of the agreement, Biond will receive an upfront payment of $125 million in cash and up to $1 billion in potential development, regulatory and sales milestones, as well as tiered double-digit royalty payments, the Israeli firm said in a statement. Biond will lead the first-in-human Phase 1a clinical trial of the drug, evaluating its safety and tolerability. Afterwards, Sanofi will take on development responsibilities and commercialization of the drug, Biond
Share this article
MISGAV, Israel, Jan. 12, 2021 /PRNewswire/
Biond Biologics Ltd. ( Biond or the Company ), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an exclusive worldwide license agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY), for the development and commercialization of BND-22.
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. ILT2, a member of the ILT family of immuno-modulating receptors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules including HLA-G, an immunosuppressive protein expressed by multiple tumor types.